Who is sponsoring NCT02326376?

NCT02326376 is sponsored by Swedish Orphan Biovitrum.

What drugs are being tested in NCT02326376?

Interventions in NCT02326376: anakinra (Kineret).

What condition does NCT02326376 study?

NCT02326376 studies Cryopyrin-Associated Periodic Syndromes.

Is NCT02326376 still recruiting?

NCT02326376 is currently completed. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT02326376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kineret CAPS Post Authorisation Study

Completed Last updated 18 January 2020

What this trial tests

trial testing anakinra (Kineret) in Cryopyrin-Associated Periodic Syndromes in 12 participants. Completed in 12 September 2019.

Timeline

24 April 2015

Primary endpoint
12 September 2019

12 September 2019

Quick facts

Lead sponsor	Swedish Orphan Biovitrum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	24 April 2015
Primary completion	12 September 2019
Estimated completion	12 September 2019
Sites	2 locations across United Kingdom, Netherlands

Drugs / interventions tested

anakinra (Kineret)

Conditions studied

Cryopyrin-Associated Periodic Syndromes — all drugs for Cryopyrin-Associated Periodic Syndromes →

Sponsor

Swedish Orphan Biovitrum — full company profile →

Who can join

Eligibility, any sex, with Cryopyrin-Associated Periodic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cryopyrin-Associated Periodic Syndromes

Currently open trials in the same condition.

NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting

Other Swedish Orphan Biovitrum trials

Trials by the same sponsor.

NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06992505 — Assessment of Macrophage Activation syndromE in STill's Disease in Italy · completed
NCT06782373 — A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · Phase 2 · recruiting
NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting
NCT06405152 — Assessment of Macrophage Activation syndromE in STill's Disease · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02326376 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swedish Orphan Biovitrum
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02326376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing